Morepen Laboratories
- Market cap
- ₹ 5,466 Cr.
- P/E
- 29x
- P/B
- 4.17x
- 52-week range
- 33.05 – 150.7
- ROE
- 5%
- ROCE
- 8%
- Dividend yield
- 0.2%
- Debt / equity
- 0.17
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Fexofenadine, Montelukast (Oral), Montelukast (Chewable), Montelukast Sodium, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen Nebulizer Model CN-11, Dr. Morepen Pulse Oximeter Model PO-12A, Dr. Morepen Breathe Free Vaporizer Model VP-06 and Dr. Morepen Pulse Oximeter Model PO-12A, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 222 companies →Morepen Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)29 against a typical 34: cheaper than most peers (1st = cheapest).93rd of 221
- Sales growth+81.1% against a typical +17.5% from a year earlier.22nd of 200
- Profit growth+117.1% against a typical +23.3% from a year earlier.26th of 163
- Share price, 3 months+2.6% against a typical −0.1%.91st of 212
- Size₹ 5,465.8 Cr. market value against a typical ₹ 485 Cr. (1st = largest).52nd of 206
Latest announcements
Exchange filings and their impact on the company.
- Morepen launched its first US prescription generic and filed its first US ANDA, a strategic step with small near-term sales.
AIAI analysisPositive for shareholdersLow impact Morepen launched its first US prescription generic and filed its first US ANDA, a strategic step with small near-term sales.
Morepen Laboratories launched its first US prescription generic, Desloratadine Tablets 5mg in 100 and 500 counts, through its US arm Morepen Bio Inc, building on years of API supply. It also filed its first US ANDA for Sitagliptin Phosphate Tablets in 25mg, 50mg and 100mg strengths, now under FDA review. The move extends Morepen from API and OTC into US finished-dose distribution, with more filings planned where its API strengths help.
Why it matters: First US Rx launch in a small mature molecule plus an ANDA under review implies only Rs 25-45 cr incremental revenue (1-2% of TTM sales) in next 12 months, strategically important but financially small.
For shareholders: Entry into higher-value US finished-dosage and first ANDA filing extends Morepen beyond API into integrated growth despite small initial scale.
Estimated effect over the next 12 months
Estimated effect over the next 12 months Metric Now Estimated change Confidence Revenue ₹ 2,286 Cr. TTM ended Sep 2026▲ +1.1% to +2% · +₹ 25 Cr. to +₹ 45 Cr. Desloratadine 5mg is a mature crowded US generic; assume 5-10% share via Morepen Bio Inc implies Rs 25-45 cr in next 12 months => 1-2% on TTM revenue of Rs 2286 cr; Sitagliptin ANDA still under review so no sales assumed55% Operating margin 12% TTM ended Sep 2026▼ −0.3 pts to −0.1 pts Commodity Rx gross margins below company average plus initial Morepen Bio Inc distribution overhead offsets small operating leverage => 10-30 bps dilution on TTM OPM of 12%45% Net profit ₹ 188 Cr. TTM ended Sep 2026▲ +1.6% to +3.2% · +₹ 3 Cr. to +₹ 6 Cr. 10-15% net margin on Rs 25-45 cr incremental Rx sales after US distribution costs => Rs 3-6 cr => 1.6-3.2% on TTM net profit of Rs 188 cr50% EPS ₹ 3.44 TTM ended Sep 2026▲ +1.5% to +3.2% · +₹ 0.05 to +₹ 0.11 Rs 3-6 cr incremental profit over about 55.5 cr shares implied by Rs 110 cr equity capital => +Rs 0.05-0.11 on TTM EPS of Rs 3.4450% Generated by AI from the original document. It can be wrong or incomplete and is not investment advice. Check the source before acting on it. Estimates are rough projections, not forecasts by Minerva Capital Research Solutions.
Morepen Laboratories launched its first US prescription generic, Desloratadine Tablets 5mg in 100 and 500 counts, through its US arm Morepen Bio Inc, building on years of API supply. It also filed its first US ANDA for Sitagliptin Phosphate Tablets in 25mg, 50mg and 100mg strengths, now under FDA review. The move extends Morepen from API and OTC into US finished-dose distribution, with more filings planned where its API strengths help.
- Q2 revenue up 81% and profit up 118% with margins doubling and Rs 317 cr contingent liability removed.
AIAI analysisVery positive for shareholdersHigh impact Q2 revenue up 81% and profit up 118% with margins doubling and Rs 317 cr contingent liability removed.
Morepen Laboratories reported very strong Q2 FY27 consolidated results with revenue of Rs 746.5 crore, up 81% from last year, and net profit of Rs 88.9 crore, up 118%. For the first half, revenue was Rs 1316.6 crore and net profit was Rs 145.3 crore, already above full FY26 profit. The company also disclosed that on 14 October 2026 the Himachal Pradesh High Court quashed a Rs 117.94 crore GST demand, removing a Rs 317.37 crore contingent liability.
Why it matters: Q2 FY27 consolidated revenue Rs 746.5 cr (+81% YoY) and net profit Rs 88.9 cr (+118% YoY) with H1 profit already 1.5x full FY26, plus High Court quashing Rs 117.94 cr GST demand and Rs 317.37 cr contingent liability, materially lifts 12-month earnings and balance-sheet outlook.
For shareholders: Revenue, margins and profits are growing sharply and a large tax contingent liability was quashed.
Estimated effect over the next 12 months
Estimated effect over the next 12 months Metric Now Estimated change Confidence Revenue ₹ 1,806 Cr. FY26 (Mar 2026)▲ +44.3% to +55.4% · +₹ 800 Cr. to +₹ 1,000 Cr. H1 FY27 revenue Rs 1316.63 cr up 57.3% YoY, Q2 Rs 746.5 cr up 81.4% YoY; annualized H1 implies ~Rs 2600-2800 cr in next 12 months85% Operating margin 7% FY26 (Mar 2026)▲ +8 pts to +10 pts Q2 EBITDA ~Rs 131.8 cr on Rs 746.5 cr revenue = ~17.6% margin, H1 ~16.7% vs 7% FY26 baseline; assumes 15-17% sustains80% Net profit ₹ 96 Cr. FY26 (Mar 2026)▲ +177.1% to +229.2% · +₹ 170 Cr. to +₹ 220 Cr. H1 FY27 net Rs 145.29 cr vs Rs 51.62 cr YoY and vs full FY26 Rs 95.65 cr; annualized ~Rs 270-315 cr implies +Rs 170-220 cr vs baseline82% EPS ₹ 1.73 FY26 (Mar 2026)▲ +179.2% to +225.4% · +₹ 3.1 to +₹ 3.9 ~54.79 cr shares; estimated annual net Rs 270-315 cr implies EPS Rs 4.9-5.7 vs 1.73 baseline82% Net debt ₹ 208 Cr. Mar 2026 borrowings▼ −33.7% to −19.2% · −₹ 70 Cr. to −₹ 40 Cr. Sep 2026 gross borrowings Rs 304.96 cr but cash+bank Rs 254.66 cr leaves net ~Rs 50 cr vs ~Rs 126 cr Mar26; strong H1 operating cash Rs 127.48 cr to reduce net debt65% Market cap ₹ 6,753.53 Cr. as of 2026-10-22▲ +29.6% to +50.3% · +₹ 2,000 Cr. to +₹ 3,400 Cr. Earnings more than doubling and removal of Rs 317.37 cr contingent liability; assume 30-50% re-rating on higher earnings base60% Working capital 122 days Mar 2026▼ −9.8% to −5.7% · −12 to −7 Sales up 81% YoY with inventories +Rs 51.8 cr and payables funding growth; scale should trim working capital days to ~110-115 days60% Capex ₹ 535 Cr. Mar 2026 fixed assets plus CWIP▲ +24.3% to +33.6% · +₹ 130 Cr. to +₹ 180 Cr. H1 purchases PPE Rs 64.78 cr plus intangibles Rs 24.87 cr; full-year run-rate implies Rs 130-180 cr addition to asset base70% Net worth ₹ 1,247 Cr. Mar 2026 equity plus reserves▲ +20% to +24.1% · +₹ 250 Cr. to +₹ 300 Cr. Estimated annual retained profit ~Rs 270-315 cr less dividend ~Rs 11 cr adds ~Rs 250-300 cr to net worth80% Generated by AI from the original document. It can be wrong or incomplete and is not investment advice. Check the source before acting on it. Estimates are rough projections, not forecasts by Minerva Capital Research Solutions.
Morepen Laboratories reported very strong Q2 FY27 consolidated results with revenue of Rs 746.5 crore, up 81% from last year, and net profit of Rs 88.9 crore, up 118%. For the first half, revenue was Rs 1316.6 crore and net profit was Rs 145.3 crore, already above full FY26 profit. The company also disclosed that on 14 October 2026 the Himachal Pradesh High Court quashed a Rs 117.94 crore GST demand, removing a Rs 317.37 crore contingent liability.
- HP High Court quashed Rs 118 cr GST refund demand, removing a profit-sized liability overhang.
AIAI analysisPositive for shareholdersHigh impact HP High Court quashed Rs 118 cr GST refund demand, removing a profit-sized liability overhang.
Morepen Laboratories said the Himachal Pradesh High Court on 12 October 2026 quashed a Central GST show cause notice seeking recovery of Rs 117.94 crore towards excess GST refund plus interest and penalty. The order, received on 14 October 2026, decides the writ petition in the company's favour. This removes a large contingent liability equal to more than a year's profit and clears a major cash-flow overhang.
Why it matters: SCN exposure of Rs 117.94 cr plus interest and penalty was ~123% of FY26 net profit of Rs 96 cr and ~9.5% of net worth of Rs 1247 cr, so its removal is highly material to cash flow and balance sheet over next 12 months.
For shareholders: Quashing removes a Rs 118 cr plus interest and penalty cash outflow risk exceeding one year of profit.
Estimated effect over the next 12 months
Estimated effect over the next 12 months Metric Now Estimated change Confidence Net profit ₹ 96 Cr. FY26 (year ended Mar 2026)▲ +122.85% · +₹ 117.94 Cr. SCN sought Rs 117.94 cr plus interest and penalty; quashing avoids cash outflow equal to ~123% of FY26 PAT of Rs 96 cr, treated as preserved profit over next 12 months85% EPS ₹ 1.73 FY26 (year ended Mar 2026)▲ +122.85% · +₹ 2.13 Rs 117.94 cr saved divided by ~55.5 cr shares implied by Rs 110 cr equity capital of Rs 2 face value and FY26 EPS of Rs 1.7385% Net debt ₹ 208 Cr. Mar 2026 balance sheet▼ −56.7% · −₹ 117.94 Cr. Borrowings Rs 208 cr as proxy for net debt; avoiding Rs 117.94 cr payment plus interest/penalty avoids equivalent increase in debt if funded by borrowing80% Net worth ₹ 1,247 Cr. Mar 2026 balance sheet▲ +9.46% · +₹ 117.94 Cr. Net worth Rs 1247 cr from equity capital Rs 110 cr plus reserves Rs 1137 cr; preserving Rs 117.94 cr avoids ~9.5% erosion of net worth85% Generated by AI from the original document. It can be wrong or incomplete and is not investment advice. Check the source before acting on it. Estimates are rough projections, not forecasts by Minerva Capital Research Solutions.
Morepen Laboratories said the Himachal Pradesh High Court on 12 October 2026 quashed a Central GST show cause notice seeking recovery of Rs 117.94 crore towards excess GST refund plus interest and penalty. The order, received on 14 October 2026, decides the writ petition in the company's favour. This removes a large contingent liability equal to more than a year's profit and clears a major cash-flow overhang.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A by Infomerics- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| Infomerics | IVR A | Stable | 17 Nov 2026 |
| Rating | Details | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17 Nov 2026 | ▲ Upgrade1 notch | IVR A- → IVR A | High | Infomerics | ₹ 225 Cr. | |||||||||||||||||||||||||||||||||||||||||||||
Rating details
Infomerics upgraded Morepen to IVR A on CDMO-led 57% revenue surge and margin tripling. Infomerics upgraded Morepen Laboratories' Rs 225 crore bank facilities from IVR A- to IVR A with Stable outlook on November 17, 2026. The agency cited a 57% jump in H1FY27 revenue to about Rs 1,317 crore and EBITDA tripling to about Rs 206 crore at 15.6% margin, driven by Rs 311 crore of commercial supplies under its Rs 825 crore CDMO contract, plus 39% growth in medical devices. It noted an unexecuted CDMO order book of about Rs 514 crore, comfortable gearing of 0.29x with Rs 171 crore cash cover, offset by single-customer concentration, working-capital intensity and restructuring of the medical devices business. Why it matters: Rs 825 cr CDMO mandate drove H1FY27 revenue to Rs 1316.63 cr (+57% YoY) and EBITDA to Rs 205.65 cr at 15.62% margin with Rs 514 cr still unexecuted, materially lifting scale, profits and debt cover while keeping gearing at 0.29x. For shareholders: CDMO commercialisation has already tripled EBITDA and pushed H1 PAT above full FY26, with Rs 514 cr order book underpinning next 12 months. Estimated effect over the next 12 months
Generated by AI from the original document. It can be wrong or incomplete and is not investment advice. Check the source before acting on it. Estimates are rough projections, not forecasts by Minerva Capital Research Solutions. | ||||||||||||||||||||||||||||||||||||||||||||||||||
| 22 Aug 2025 | New rating | IVR A- | — | Infomerics | ₹ 225 Cr. | |||||||||||||||||||||||||||||||||||||||||||||
Rating details
First rating on file, as stated by the agency No AI analysis yet for this rating. The agency's rationale has the full reasoning. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 27 Oct 2026 | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 4 Aug 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 26 May 2026 | Financial Results/Dividend/Other business matters | MOREPENLAB : 26-May-2026 : The Company has informed the Exchange that a Board meeting to be held on May 22, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 26, 2026, To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters |
| 10 Feb 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 14 Nov 2025 | Financial Results | To consider and approve un-audited standalone and consolidated financial results of the company for the quarter and half year ended 30th September 2025 |
| 6 Aug 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 445 | 423 | 455 | 438 | 453 | 466 | 425 | 412 | 484 | 485 | 570 | 746 |
| Expenses | 394 | 375 | 404 | 394 | 417 | 424 | 401 | 381 | 438 | 460 | 488 | 623 |
| Operating Profit | 51 | 48 | 52 | 44 | 36 | 42 | 24 | 31 | 46 | 24 | 83 | 123 |
| OPM % | 11% | 11% | 11% | 10% | 8% | 9% | 6% | 7% | 10% | 5% | 14% | 16% |
| Other Income | 4 | 4 | 3 | 5 | 5 | 5 | 4 | 30 | 4 | 8 | 5 | 9 |
| Interest | 2 | 1 | 1 | 1 | 1 | 5 | 4 | 4 | 4 | 4 | 5 | 5 |
| Depreciation | 8 | 10 | 6 | 2 | 5 | 16 | 9 | 11 | 10 | 6 | 8 | 10 |
| Profit before tax | 44 | 42 | 48 | 46 | 35 | 26 | 16 | 46 | 35 | 23 | 75 | 117 |
| Tax % | 27% | 32% | 25% | 24% | 24% | 21% | 26% | 10% | 22% | 33% | 24% | 24% |
| Net Profit | 32 | 29 | 36 | 35 | 27 | 20 | 11 | 41 | 28 | 16 | 56 | 89 |
| EPS in Rs | 0.63 | 0.55 | 0.71 | 0.64 | 0.49 | 0.37 | 0.2 | 0.75 | 0.5 | 0.29 | 1.03 | 1.62 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 14%
- 5 Years
- 9%
- 3 Years
- 8%
- TTM
- 30%
- 10 Years
- 14%
- 5 Years
- −8%
- 3 Years
- 18%
- TTM
- 150%
- 10 Years
- 19%
- 5 Years
- 21%
- 3 Years
- 59%
- TTM
- —
- 10 Years
- 12%
- 5 Years
- 10%
- 3 Years
- 9%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Morepen Laboratories | ₹ 90.75 | ₹ 5,466 Cr. | 29x | 4.2x | 5% | — |
| Sun Pharmaceutical Industries | ₹ 1,880.00 | ₹ 4,51,064 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 11,442.00 | ₹ 3,03,749 Cr. | 73x | 11.4x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,662.15 | ₹ 1,77,327 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,391.80 | ₹ 1,12,438 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,189.90 | ₹ 1,18,693 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Sushil Suri
- Executive Chairman of the Board, Managing Director
- Ajay Kumar Sharma
- Chief Financial Officer
- Vipul Kumar Srivastava
- Compliance Officer, Company Secretary
- Sanjay Suri
- Managing Director
Prices are delayed and for information only. Nothing on this page is investment advice.